natgillin/translations-raw huggingface dataset:
Children, adolescents and adults with polyarticular juvenile idiopathic arthritis Children, adolescents and adults from 2 years of age weighing 30 kg or more The recommended dose of Halimatoz is 40 mg every other week. 
Otroci, mladostniki in odrasli s poliartikularnim juvenilnim idiopatskim artritisom Otroci, mladostniki in odrasli, starejši od 2 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Halimatoz je 40 mg vsak drugi teden.
The recommended dose of Halimatoz for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Halimatoz pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.
• It is important that you tell your baby's doctors and other health care professionals about your Halimatoz use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section). 
• Pomembno je, da obvestite zdravnika vašega dojenčka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Halimatoz, preden bo vaš dojenček prejel katerokoli cepivo.
Package leaflet: Information for the patient Halimatoz 40 mg solution for injection in pre-filled syringe adalimumab This medicine is subject to additional monitoring. 
Navodilo za uporabo Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab Za to zdravilo se izvaja dodatno spremljanje varnosti.
The recommended dose of Halimatoz for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Halimatoz za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
The recommended dose of Halimatoz for patients with Crohn's disease from 6 to 17 years of age is based on body weight (table 4). 
Priporočeni odmerek zdravila Halimatoz pri bolnikih s Crohnovo boleznijo, starih od 6 do 17 let, temelji na telesni masi (preglednica 4).
If these medicines do not work well enough, you will be given Halimatoz to treat your rheumatoid arthritis. 
Če ta zdravila ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Halimatoz.
Halimatoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Cartons contain 1 and 2 pre-filled syringes of Halimatoz. 
Škatle vsebujejo 1 in 2 napolnjena injekcijska peresnika zdravila Halimatoz.
Halimatoz is used to treat rheumatoid arthritis in adults. 
Zdravilo Halimatoz se uporablja za zdravljenje revmatoidnega artritisa pri odraslih.
Halimatoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen (SensoReady) with transparent window and label. 
Zdravilo Halimatoz je na voljo v injekcijski brizgi za enkratno uporabo, v injekcijskem peresniku trikotne oblike (SensoReady), s prozornim okencem in oznako.
Each syringe contains 40 mg/0.8 ml of Halimatoz. 
Ena injekcijska brizga vsebuje 40 mg/0,8 ml zdravila Halimatoz.
During treatment with Halimatoz, other concomitant therapies (e.g., corticosteroids and / or immunomodulatory agents) should be optimised. 
Med zdravljenjem z zdravilom Halimatoz je treba optimizirati druge sočasne terapije (npr.
Halimatoz is indicated for treatment of moderately to severely active Crohn's disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. 
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri odraslih bolnikih, ki se ne odzovejo na popoln in ustrezen ciklus zdravljenja s kortikosteroidom in/ali imunosupresivom, ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Halimatoz is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age. 
Zdravilo Halimatoz se uporablja za zdravljenje hidradenitis suppurativa pri odraslih in mladostnikih,
Children, adolescents and adults with enthesitis-related arthritis Children, adolescents and adults from 6 years of age weighing 30 kg or more The recommended dose of Halimatoz is 40 mg every other week. 
Otroci, mladostniki in odrasli z artritisom, povezanim z entezitisom Otroci, mladostniki in odrasli, starejši od 6 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Halimatoz je 40 mg vsak drugi teden.
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class (SOC) and frequency in table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data). 
zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do
Polyarticular juvenile idiopathic arthritis from 2 years of age 
Poliartikularni juvenilni idiopatski artritis od 2. do 12. leta starosti.
Halimatoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. 
Ankilozirajoči spondilitis (AS) Zdravilo Halimatoz je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
There is no relevant use of Halimatoz in children aged less than 2 years in this indication. 
Uporaba zdravila Halimatoz pri otrocih, mlajših od 2 let, za to indikacijo ni primerna.
Multipack cartons contain 6 (3 packs of 2) pre-filled syringes of Halimatoz. 
Škatle za večkratno pakiranje vsebujejo 6 (3 pakiranja po 2) napolnjenih injekcijskih brizg zdravila Halimatoz.
Halimatoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. 
Uveitis pri pediatričnih bolnikih Zdravilo Halimatoz je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri bolnikih, ki so starejši od 2 let in se niso ustrezno odzvali na konvencionalno zdravljenje, ga ne prenašajo ali pri katerih konvencionalno zdravljenje ni primerno.
Halimatoz 40 mg solution for injection in pre-filled syringe Halimatoz 40 mg solution for injection in pre-filled pen 
Halimatoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Halimatoz is administered by subcutaneous injection. 
Zdravilo Halimatoz se uporablja kot subkutana injekcija.
If you do not respond well enough to these medicines, you will be given Halimatoz to reduce the signs and symptoms of your Crohn's disease. 
Če se nanje ne boste odzvali dovolj dobro, boste za zmanjšanje znakov in simptomov Crohnove bolezni dobili zdravilo Halimatoz.
• Do not give Halimatoz to children with polyarticular juvenile idiopathic arthritis below the age of 
• Zdravila Halimatoz ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom,
EU/1/18/1288/001 1 pre-filled syringe EU/1/18/1288/002 2 pre-filled syringes 
EU/1/18/1288/001 1 napolnjena injekcijska brizga EU/1/18/1288/002 2 napolnjeni injekcijski brizgi
The recommended Halimatoz dose for patients with plaque psoriasis from 4 to 17 years of age is based on body weight (table 3). 
Priporočeni odmerek zdravila Halimatoz pri bolnikih s psoriazo v plakih, starih od 4 do 17 let, temelji na telesni masi (preglednica 3).
Halimatoz dose for patients with enthesitis-related arthritis Patient weight 
Odmerjanje zdravila Halimatoz pri bolnikih z artritisom, povezanim z entezitisom
Halimatoz is used to treat psoriatic arthritis in adults. 
Zdravilo Halimatoz se uporablja za zdravljenje psoriatičnega artritisa pri odraslih.
Halimatoz dose for paediatric patients with plaque psoriasis Patient weight 
Odmerjanje zdravila Halimatoz pri pediatričnih bolnikih s psoriazo v plakih
EU/1/18/1288/006 6 pre-filled pens (3 packs of 2) 
EU/1/18/1288/006 6 napolnjenih injekcijskih peresnikov (3 pakiranja po 2)
Cartons contain 1 and 2 pre-filled pens of Halimatoz. 
Škatle vsebujejo 1 in 2 napolnjeni injekcijski brizgi zdravila Halimatoz.
Thus, it is not possible to administer Halimatoz to paediatric patients that require less than a full 40 mg dose. 
Zato zdravila Halimatoz ni mogoče dajati pediatričnim bolnikom, ki potrebujejo odmerek, manjši od 40 mg.
Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Halimatoz. 
salicilatov, nesteroidnih protivnetnih zdravil ali analgetikov.
Halimatoz is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. 
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri pediatričnih bolnikih (od 6. leta starosti), ki se ne odzovejo zadovoljivo na konvencionalno zdravljenje, vključno s primarno prehransko terapijo in kortikosteroidom in/ali imunomodulatorjem,
Your Halimatoz single-use pre-filled syringe with needle guard and add-on finger flange 
Vaša napolnjena injekcijska brizga zdravila Halimatoz z varovalnim pokrovčkom in držalom
Halimatoz is used to treat ulcerative colitis in adults. 
Zdravilo Halimatoz se uporablja za zdravljenje ulceroznega kolitisa pri odraslih.
The recommended Halimatoz dose is 80 mg at week 0 followed by 40 mg every other week starting at week 1 via subcutaneous injection. 
Priporočeni odmerek zdravila Halimatoz je 80 mg v 0. tednu, ki mu sledi 40 mg vsak drugi teden z začetkom v 1. tednu, v obliki subkutane injekcije.
• skin infections (including cellulitis and shingles); 
• črevesne okužbe (vključno z gastroenteritisom); • okužbe kože (vključno s celulitisom in pasovcem);
Thus, it is not possible to administer Halimatoz to patients that require less than a full 40 mg dose. 
Zato zdravila Halimatoz ni mogoče dajati bolnikom, ki potrebujejo odmerek, manjši od 40 mg.
Systemic infections (including sepsis, candidiasis and influenza), intestinal infections (including gastroenteritis viral), skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster), ear infections, oral infections (including herpes simplex, oral herpes and tooth infections), reproductive tract infections (including vulvovaginal mycotic infection), urinary tract infections (including pyelonephritis), fungal infections, joint infections 
okužbe ustne votline (vključno s herpesom simpleksom, ustnim herpesom in okužbami zob), okužbe reproduktivnega trakta (vključno z vulvovaginalno mikotično okužbo), okužbe urinarnega trakta (vključno s pielonefritisom),
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of nonmelanoma skin cancer prior to and during treatment with Halimatoz. 
Pred zdravljenjem z zdravilom Halimatoz in med zdravljenjem z njim je treba za nemelanomskega kožnega raka pregledati vse bolnike, še zlasti pa bolnike z anamnezo intenzivne imunosupresivne terapije in bolnike s psoriazo, ki so kdaj prejemali PUVA.
Halimatoz is only available as 40 mg pre-filled syringe and 40 mg pre-filled pen. 
Zdravilo Halimatoz je na voljo samo v 40 mg napolnjeni injekcijski brizgi in 40 mg napolnjenem injekcijskem peresniku.
How to store Halimatoz 
Shranjevanje zdravila Halimatoz
EU/1/18/1288/004 1 pre-filled pen EU/1/18/1288/005 2 pre-filled pens 
EU/1/18/1288/004 1 napolnjen injekcijski peresnik EU/1/18/1288/005 2 napolnjena injekcijska peresnika
• Halimatoz pre-filled syringe/s (see Figure A). 
• napolnjen(a) injekcijski(a) peresnik(a) (glejte sliko A).
In adolescent patients with inadequate response to Halimatoz 40 mg every other week, an increase in dosage to 40 mg every week or 80 mg every other week may be considered. 
Pri mladostnikih z nezadostnim odzivom na zdravilo Halimatoz 40 mg vsak drugi teden je možno razmisliti o povečanju odmerka na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz is used to treat moderate to severe plaque psoriasis in adults. 
Zdravilo Halimatoz se uporablja za zdravljenje zmerne do hude luskavice (psoriaze) v plakih pri odraslih.
Talk to your doctor or pharmacist before using Halimatoz. 
Pred začetkom uporabe zdravila Halimatoz se posvetujte z zdravnikom ali farmacevtom.
Be sure that you read, understand, and follow these Instructions for use before injecting Halimatoz. 
Preden injicirate zdravilo Halimatoz, morate ta navodila za uporabo prebrati, razumeti in jih upoštevati.
RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old, had failed therapy with at least one disease-modifying, anti-rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25 mg every week. 
V študiji revmatoidnega artritisa I je bilo ocenjeno 271 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno, pri katerih metotreksat v odmerkih od 12,5 do 25 mg
Beyond 16 weeks, patients with inadequate response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg every week or 80 mg every other week. 
Od 16. tedna dalje lahko bolnikom z nezadostnim odzivom na zdravilo Halimatoz 40 mg vsak drugi teden koristi povečanje odmerka na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz is only available as 40 mg pre-filled syringe / pre-filled pen. 
Zdravilo Halimatoz je na voljo samo v 40 mg napolnjeni injekcijski brizgi/napolnjenem injekcijskem peresniku.
Carriers of HBV who require treatment with Halimatoz should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. 
Pri bolnikih, ki so pozitivni na okužbo s hepatitisom B, se priporoča posvetovanje z zdravnikom specialistom za zdravljenje okužb s hepatitisom B. Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Halimatoz, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV. O zdravljenju nosilcev HBV s protivirusno terapijo v kombinaciji z antagonistom TNF za preprečitev reaktivacije HBV ni zadostnih podatkov.
The recommended dose of Halimatoz for patients with enthesitis-related arthritis from 6 years of age is based on body weight (table 2). 
Priporočeni odmerek zdravila Halimatoz pri bolnikih z artritisom, povezanim z entezitisom, starih 6 let in več, temelji na telesni masi (preglednica 2).
Your healthcare provider should show you how to prepare and inject Halimatoz properly using the prefilled syringe before you use it for the first time. 
Preden zdravilo Halimatoz prvič uporabite, vam mora zdravstveni delavec pokazati, kako ga pravilno pripraviti in injicirati z napolnjeno injekcijsko brizgo.
Halimatoz is supplied in a single-use clear type I glass syringe with a stainless steel needle with a needle guard with finger flange, rubber needle cap and plastic plunger rod, containing 0.8 ml of solution. 
Zdravilo Halimatoz je na voljo v injekcijski brizgi za enkratno uporabo iz prozornega stekla tipa I z iglo iz nerjavečega jekla s ščitnikom za iglo z držalom, z gumijastim pokrovčkom za iglo in s plastičnim batom, ki vsebuje 0,8 ml raztopine.
Halimatoz 40 mg solution for injection in pre-filled syringe adalimumab 
Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab
In monotherapy, some patients who experience a decrease in their response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other week. 
Med monoterapijo lahko nekaterim bolnikom, ki se jim zmanjša odziv na zdravilo Halimatoz 40 mg vsak drugi teden, koristi povečanje odmerka adalimumaba na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz should be used with caution in patients with mild heart failure (NYHA class I/II). 
Pri bolnikih z blagim srčnim popuščanjem (razred I/II po NYHA) je treba zdravilo Halimatoz uporabljati previdno.
Some patients who experience decrease in their response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg Halimatoz every week or 80 mg every other week. 
Nekaterim bolnikom, ki se jim zmanjša odziv na zdravilo Halimatoz 40 mg vsak drugi teden, lahko koristi povečanje odmerka zdravila Halimatoz na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz 40 mg solution for injection (injection) in pre-filled syringe is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution. 
Zdravilo Halimatoz 40 mg raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Halimatoz is available as a pre-filled syringe and a pre-filled pen (SensoReady). 
Zdravilo Halimatoz je lahko na voljo v napolnjeni injekcijski brizgi in napolnjenem injekcijskem peresniku (SensoReady).
The recommended dose of Halimatoz for adult patients with uveitis is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose. 
Priporočeni začetni odmerek zdravila Halimatoz za odrasle bolnike z uveitisom je 80 mg, čemur sledi 40 mg odmerek vsak drugi teden, ki se ga začne dajati en teden po začetnem odmerku.
Halimatoz 40 mg solution for injection (injection) in pre-filled pen is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution. 
Zdravilo Halimatoz 40 mg raztopina za injiciranje (injekcija) v napolnjenem injekcijskem peresniku je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Halimatoz 40 mg solution for injection in single-use pre-filled SensoReady pen Halimatoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label (SensoReady). 
Zdravilo Halimatoz je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo, v peresniku trikotne oblike s prozornim okencem in oznako (peresnik SensoReady®).
The recommended dose of Halimatoz for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the initial dose. 
Priporočeno odmerjanje zdravila Halimatoz za odrasle bolnike je začetni odmerek 80 mg subkutano in nato 40 mg subkutano vsak drugi teden, začenši en teden po začetnem odmerku.
Discontinuation of Halimatoz therapy should be considered in patients with confirmed significant haematologic abnormalities. 
Pri bolnikih s potrjenimi pomembnimi hematološkimi nepravilnostmi je treba razmisliti o prekinitvi terapije z zdravilom Halimatoz.
Halimatoz is administered via subcutaneous injection. 
Zdravilo Halimatoz se odmerja v obliki subkutane injekcije.
The syringe inside the pen is made of type I glass with a stainless steel needle, an inner rubber needle cap, and a rubber stopper, containing 0.8 ml solution. 
Brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečegaa jekla, notranjim gumijastim pokrovčkom za iglo in gumijasto zaporko, ki vsebuje 0,8 ml raztopine.
Halimatoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1). 
Zdravilo Halimatoz je indicirano za zdravljenje aktivnega artritisa, povezanega z entezitisom pri bolnikih, starih 6 let in več, ki so se neustrezno odzvali ali so intolerantni za običajno zdravljenje
The recommended dose of Halimatoz is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg every other week starting one week later. 
Priporočeno odmerjanje zdravila Halimatoz je začetni odmerek 80 mg (kot dve 40 mg injekciji v enem dnevu), čemur sledi 40 mg vsaka dva tedna z začetkom en teden po začetnem odmerku.
The recommended Halimatoz induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160 mg at week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days) and 80 mg at week 2 (given as two 40 mg injections in one day). 
Priporočena shema odmerjanja zdravila Halimatoz med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivnim ulceroznim kolitisom 160 mg 0. teden (aplicirano kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva dni zapored) in 80 mg 2. teden (aplicirano kot dve 40 mg injekciji v enem dnevu).
The usual Halimatoz dose for adults with ulcerative colitis is 160 mg initially (as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), then 80 mg (as two 40 mg injections) two weeks later, and then 40 mg every other week. 
Običajni začetni odmerek zdravila Halimatoz pri odraslih z ulceroznim kolitisom je 160 mg (kot štiri 40 mg injekcije v enem dnevu ali po dve 40 mg injekciji na dan dva zaporedna dneva), nato 80 mg (kot dve 40 mg injekciji) dva tedna pozneje in nato 40 mg vsaka dva tedna.
The recommended Halimatoz dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one day). 
Priporočena shema odmerjanja zdravila Halimatoz pri odraslih bolnikih s hidradenitis suppurativa (HS) je 160 mg na 1. dan (apliciranov obliki štirih 40 mg injiciranj na dan ali z dvema 40 mg injiciranjema na dan dva dni zapored), ki mu sledi 80 mg dva tedna kasneje na 15. dan (apliciranov obliki dveh 40 mg injiciranj v enem dnevu).
The syringe inside the pen is made of type I glass with a stainless steel needle and an inner rubber needle cap, containing 0.8 ml of solution. 
Injekcijska brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečega jekla in notranjim gumijastim pokrovčkom za iglo ter vsebuje 0,8 ml raztopine.
Halimatoz dose for paediatric patients with uveitis Patient weight 
Odmerjanje zdravila Halimatoz pri pediatričnih bolnikih z uveitisom
Your Halimatoz single-use pre-filled SensoReady pen 
Vaš napolnjeni injekcijski peresnik SensoReady zdravila Halimatoz za enkratno uporabo
Vertigo and visual impairment may occur following administration of Halimatoz (see section 4.8). 
Po dajanju zdravila Halimatoz se lahko pojavita vrtoglavica in poslabšanje vida (glejte poglavje 4.8).
Halimatoz is contraindicated in moderate to severe heart failure (see section 4.3). 
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Halimatoz kontraindicirano (glejte poglavje 4.3).